Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Prism Pharma Co., Ltd.

Prism Biolab Co., Ltd.

Yoichi Ozawa

Takashi Owa

Taro Semba

Naoko Hata

Norihiro Ueda

Yasuhiro Funahashi

Akihiko Tsuruoka

Keiko Takahashi

Yuji Yamamoto

Tadashi Okabe

Toru Haneda

Kazumasa Nara

Junichi Kamata

Shinichi Hamaoka

Toshiaki Wakabayashi

Takeshi Nagasu

Nozomu Koyanagi

Hiroshi Yoshino

Kentaro Yoshimatsu

Kyosuke Kito

Noako Tsukahara

Tatsuo Okauchi

Ken Ito

Yoshimasa Sakamoto

Junji Matsui

Kishan Agarwala

Yusaku Hori

Yu Kato

Masahiko Katayama

Naoko Sugi

Yusuke Adachi

Takanori Abe

Yuya Nakazawa

Sho Tachino

Katsuhisa Suzuki

Kana Hoshino

Takayuki Hida

Hiroyuki Kouji

Norimasa Miyamoto

Takenao Odagami

Bruce A Littlefield

Naoko Tsukahara

Kazuhiko Yamada

Masahiro Matsuki

Hiroshi Kamiyama

Martin Olivo

Makoto Asano

Yanke Yu

Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.

Tumor-treating pharmaceutical composition

The present invention aims to provide a therapeutic drug for cancer having a superior treatment effect. A cancer treatment using a CBP/catenin inhibitor and an immune checkpoint inhibitor in combination not only increases a treatment effect on cancer, but also enables an effective treatment of cancer patients showing low sensitivity when an immune checkpoint inhibitor is used alone.

Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor

The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.

Anti human Notch4 antibody

The present invention relates to pharmaceutical compositions comprising a sulfonamide-including compound in combination with an angiogenesis inhibitor.

Use of sulfonamide-including compounds in combination with angiogenesis inhibitors

An appetite-stimulating agent and a therapeutic agent for anorexia, each comprising, as an active ingredient, a sulfonamide derivative or sulfonic acid ester derivative represented by the following general formula (I):

Appetite-stimulating agents and remedies for anorexia

Sulfonamide-containing heterocyclic compounds

Sulfonamide-containing indole compounds

Novel heterobicyclic sulfonamide and sulfonic ester derivatives represented by the following general formula (I), which exhibit an antitumor activity and are lowly toxic, and processes for the preparation thereof. A sulfonamide derivative and a sulfonic ester derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof: ##STR1## wherein variables A, W, X, B, C, Y, Z are as defined in the specification.

7-Amino-1H-indoles

Heterobicyclic sulfonamide and sulfonic ester derivatives

Growing community of inventors

Tsukuba, Japan

Yoichi Ozawa